Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MMX Mesalazine/mesalamine+ Ciprofloxacin · 1 trial · 1 indication
AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.
Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.
| Arm | Type | Description |
|---|---|---|
| Ciprofloxacin + MMX placebo | EXPERIMENTAL | - |
| MMX Mesalazine/mesalamine + Ciprofloxacin | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Ciprofloxacin XR + MMX Placebo | DRUG | MMX Mesalazine/mesalamine placebo dosed once-a-day (QD) orally for 3 days, then a single oral 500 mg dose of ciprofloxacin XR + a single oral dose of MMX Mesalazine/mesalamine placebo on day 4 |
| MMX Mesalazine/mesalamine + Ciprofloxacin XR | DRUG | MMX Mesalazine/mesalamine 4.8 g QD orally for 3 days, then a single oral 500 mg dose of ciprofloxacin XR + a single oral dose 4.8 g of MMX Mesalazine/mesalamine on day 4 |
Inclusion Criteria 1. Age 18-55 years inclusive at the time of consent. The date of signing informed consent is defined as the beginning of the Screening Period. 2. Subject is willing to comply with any applicable contraceptive requirements of the protocol and is: * Male, or * Non-pregnant, ...
MMX Mesalazine/mesalamine + Ciprofloxacin is a combination of two small molecules being studied in healthy volunteers. It is currently in Phase 1 clinical development, with the completed trial NCT01402947 evaluating the drug interaction between Ciprofloxacin XR and MMX Mesalazine/Mesalamine. The study enrolled 30 participants in the United States.
Takeda Pharmaceutical Company Limited (ticker: TAK) is developing MMX Mesalazine/mesalamine + Ciprofloxacin. The drug is a small molecule combination therapy currently in Phase 1 clinical trials. Takeda conducted a completed Phase 1 study (NCT01402947) in healthy volunteers to assess the drug interaction between the two components.
MMX Mesalazine/mesalamine + Ciprofloxacin is in Phase 1 clinical development. The drug has one completed Phase 1 trial (NCT01402947) with 30 enrolled participants. It is investigational and not yet approved for any indication. The study was conducted in healthy volunteers in the United States.
MMX Mesalazine/mesalamine + Ciprofloxacin has one completed clinical trial, NCT01402947, titled 'Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine/Mesalamine.' This Phase 1 study enrolled 30 healthy volunteers in the United States, with participants aged 18 years and older. The trial was controlled and randomized but not double-blind.
MMX Mesalazine/mesalamine + Ciprofloxacin is a combination of two drugs: mesalazine (also known as mesalamine) and ciprofloxacin. It is not the same as either drug alone, as it combines both active ingredients in a single product. The Phase 1 trial studied the drug interaction between Ciprofloxacin XR and MMX Mesalazine/Mesalamine.